Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study

BACKGROUND: Oral and intravenous formulations of ciprofloxacin have established efficacy and safety profiles in respiratory infections. A dry powder for inhalation (DPI) that uses Novartis’ PulmoSphere™ technology has been developed to deliver high concentrations of ciprofloxacin to the lung with lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Stass, Heino, Nagelschmitz, Johannes, Willmann, Stefan, Delesen, Heinz, Gupta, Abhishek, Baumann, Sybille
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing AG 2013
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664741/
https://www.ncbi.nlm.nih.gov/pubmed/23605507
http://dx.doi.org/10.1007/s40261-013-0082-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664741/
https://www.ncbi.nlm.nih.gov/pubmed/23605507
http://dx.doi.org/10.1007/s40261-013-0082-0

Ejemplares similares